I'm adding Prolactin (Stem Cell Therapeutics / U of Calgary) to the phase 1 list based on a bunch of stuff. Thanks to Marcy for the tip.
From the Stem Cell Network:
Endogenous progenitor cell repair in multiple sclerosis (Core)
Investigators: Samuel Weiss (project leader), University of Calgary; Voon Wee Yong, University of Calgary; Jack Antel, McGill University; Luanne Metz, University of Calgary.
Project summary: Building on previously funded SCN research, this project includes basic research and a clinical trial to identify and test the role of prolactin, a pituitary hormone, in the repair of damaged myelin in patients with Multiple Sclerosis (MS).
Partners: Swartout Centre for MS Neuroprotection and Repair – Hotchkiss Brain Institute; Neuroscience Canada Foundation; Stem Cell Therapeutics Corp.
Benefits: The overall goal is to develop a novel therapeutic approach to treat MS patients.
From Stem Cell Therapeutics (SCT):
SCT has substantial intellectual property relating to the use of neurogenic agents for treating demyelinating diseases such as multiple sclerosis (MS). Previous scientific investigations have characterized two potentially important therapeutic effects of prolactin on the CNS. In these published studies prolactin has been shown to act as both a neurogenic agent to increase the number of progenitor cells that mature into oligodendrocytes and as an agent that promotes remyelination of the brain in the presence of disease conditions. SCT was recently granted two key patents for the use of prolactin in neurologic diseases authored by Dr. Samuel Weiss from the University of Calgary and based on demonstrated insights into the effect of prolactin. Moreover, recent publications (Journal of Neuroscience, Feb. 21, 2007 ‘White Matter Plasticity and Enhanced Remyelination in Maternal CNS’ by Drs Yong and Weiss) strongly support and validate the concept that prolactin may represent a potential new therapeutic platform for the treatment of white matter injury, and an mpetus for a clinical program aimed at treating patients with multiple sclerosis. Successful completion of a preliminary non-clinical study undertaken by Dr Wee Yong at University of Calgary is expected to quickly evolve into a clinical program to demonstrate efficacy in patients diagnosed with multiple sclerosis. The results of this study are anticipated to be announced in early 2009, and the follow-on clinical study that will be lead by Dr Luann Metz at the University of Calgary is anticipated to begin in Q3 2009. This study is expected to be funded by an outside grant to the University of Calgary.
A couple of other miscellaneous links:
- http://cnrp.marketwire.com/cnrp_files/2 ... 707sss.pdf
- http://cnrp.marketwire.com/cnrp_files/2 ... 09SSS1.pdf